The COVID-19 vaccine participant whose unexpected illness put the AstraZeneca trials on pause came down with an inflammatory syndrome known as transverse myelitis, according to a report. The ...

Why AstraZeneca is on investors’ radar today AstraZeneca (LSE:AZN) has drawn attention after a period of solid recent share ...

Astrazeneca boss Pascal Soriot was handed his largest ever pay package last year - taking his total earnings at the pharma giant to £168million.

Fact check - Latin Dictionary invalidate the translation of "the path to death" because the phrase 'a stra ze neca' is unknown.

By Pushkala Aripaka, Bhanvi Satija and Maggie Fick LONDON, Feb 10 (Reuters) - AstraZeneca forecast steady profit growth in 2026 on Tuesday, banking on strong demand for cancer drugs and new launches ...

AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration - though much of what it is ...

LONDON - AstraZeneca’s COVID-19 vaccine provided strong protection against disease and complete protection against hospitalization and death across all age groups in a late-stage U.S. study, the ...

AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining tight-lipped on how the candidate actually performed. | AstraZeneca is ...

AstraZeneca PLC is a leading global pharmaceutical company with strong growth in oncology, diversified revenues, and a robust pipeline. AZN's financials show improving margins, rising EPS, and ...

AstraZeneca AZN is scheduled to report fourth-quarter and full-year 2025 results on Feb. 10, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 4.39% ...